Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  2. NAUT

(NAUT)

0.00

0.00 (0.00%)

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
18.03.2026

Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators' expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis

Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
06.03.2026

Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
26.02.2026

Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
19.02.2026

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference

SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference.

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
03.11.2025

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform  • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data presentation at the 2025 HUPO World Congress seminar “Redefining Proteomics with Single-Molecule Iterative Mapping” on November 10

Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
28.10.2025

Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Kentaro Suzuki - Chief Marketing Officer Anna Mowry - CFO & Treasurer Conference Call Participants Ji-Yon Yi William Ruby - TD Cowen, Research Division Presentation Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call.

Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript
01.08.2025

Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2025 Earnings Call July 31, 2025 8:30 AM ET Company Participants Anna Mowry - CFO & Treasurer Parag Mallick - Co-Founder, Chief Scientist & Director Sujal M. Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.

Видео

No Data

There is no data to display